DK97890D0 - Fremgangsmaade til fremstilling af mevalolactonanaloge - Google Patents

Fremgangsmaade til fremstilling af mevalolactonanaloge

Info

Publication number: DK97890D0
Authority: DK; Denmark
Prior art keywords: hydrogen; benzyloxy; phenoxy; trifluoromethyl; fluoro
Prior art date: 1982-11-22

Application number

DK097890A

Other languages

English (en)

Other versions

DK165244B (da

DK165244C (da

DK97890A (da

Inventor

Faizulla Gulamhusein Kathawala

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-22

Filing date

1990-04-19

Publication date

1990-04-19

1990-04-19 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-04-19 Publication of DK97890D0 publication Critical patent/DK97890D0/da

1990-04-19 Publication of DK97890A publication Critical patent/DK97890A/da

1992-10-26 Publication of DK165244B publication Critical patent/DK165244B/da

1993-03-22 Application granted granted Critical

1993-03-22 Publication of DK165244C publication Critical patent/DK165244C/da

Links

229910052739 hydrogen Inorganic materials 0.000 abstract 12
239000001257 hydrogen Substances 0.000 abstract 12
150000002431 hydrogen Chemical group 0.000 abstract 7
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
-1 t-butoxy Chemical group 0.000 abstract 6
125000001153 fluoro group Chemical group F* 0.000 abstract 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1
150000003839 salts Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Indole Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK097890A 1982-11-22 1990-04-19 Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler DK165244C (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US44366882A	1982-11-22	1982-11-22
US44366882		1982-11-22
US54885083A	1983-11-04	1983-11-04
US54885083		1983-11-04
EP8300308		1983-11-18
PCT/EP1983/000308 WO1984002131A1 (en)	1982-11-22	1983-11-18	Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals

Publications (4)

Publication Number	Publication Date
DK97890D0 true DK97890D0 (da)	1990-04-19
DK97890A DK97890A (da)	1990-04-19
DK165244B DK165244B (da)	1992-10-26
DK165244C DK165244C (da)	1993-03-22

Family

ID=27033614

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK359284A DK359284A (da)	1982-11-22	1984-07-20	Mevalolactonanaloge
DK097890A DK165244C (da)	1982-11-22	1990-04-19	Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK359284A DK359284A (da)	1982-11-22	1984-07-20	Mevalolactonanaloge

Country Status (18)

Country	Link
EP (1)	EP0114027B1 (da)
JP (1)	JPH0347167A (da)
AT (1)	ATE31718T1 (da)
AU (1)	AU570021B2 (da)
CA (1)	CA1210405A (da)
CY (1)	CY1579A (da)
DE (2)	DE3375137D1 (da)
DK (2)	DK359284A (da)
FI (1)	FI77228C (da)
GR (1)	GR79042B (da)
HK (1)	HK11191A (da)
HU (1)	HU204253B (da)
IE (1)	IE56262B1 (da)
IL (1)	IL70286A (da)
LU (1)	LU88670I2 (da)
NL (1)	NL950022I2 (da)
NZ (1)	NZ206338A (da)
WO (1)	WO1984002131A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5354772A (en) *	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) *	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
ATE60571T1 (de) *	1984-12-04	1991-02-15	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US5001255A (en) *	1984-12-04	1991-03-19	Sandoz Pharm. Corp.	Idene analogs of mevalonolactone and derivatives thereof
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
US4851427A (en) *	1985-10-25	1989-07-25	Sandoz Pharm. Corp.	Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
EP0221025A1 (en) *	1985-10-25	1987-05-06	Sandoz Ag	Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
IL83821A0 (en) *	1986-09-10	1988-02-29	Sandoz Ag	Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
US4751235A (en) *	1986-12-23	1988-06-14	Sandoz Pharm. Corp.	Anti-atherosclerotic indolizine derivatives
US4735958A (en) *	1986-12-22	1988-04-05	Warner-Lambert Company	Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) *	1987-02-25	1990-02-06	Bristol-Myers Company	Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4894386A (en) *	1987-04-15	1990-01-16	Ici Americas Inc.	Aliphatic carboxamides
US4904646A (en) *	1987-05-22	1990-02-27	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) *	1987-05-22	1992-02-25	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5185328A (en) *	1987-08-20	1993-02-09	Nissan Chemical Industries Ltd.	Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
JP2569746B2 (ja) *	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
CA1336714C (en) *	1987-08-20	1995-08-15	Yoshihiro Fujikawa	Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
DE3739882A1 (de) *	1987-11-25	1989-06-08	Bayer Ag	Substituierte hydroxylamine
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0326386A3 (en) *	1988-01-27	1990-04-25	May & Baker Limited	Isoquinolinones
US4822799A (en) *	1988-01-27	1989-04-18	Sandoz Pharm. Corp.	Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) *	1988-02-25	1989-08-28	Bayer Ag	Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) *	1988-04-26	1991-06-18	Nissan Chemical Industries Ltd.	Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) *	1988-04-26	1999-05-17	日産化学工業株式会社	ピラゾロピリジン系メバロノラクトン類
US4870187A (en) *	1988-08-23	1989-09-26	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl compounds
US5010205A (en) *	1988-08-23	1991-04-23	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl intermediates
NZ230121A (en) *	1988-08-29	1993-08-26	Squibb & Sons Inc	Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
KR0162656B1 (ko) *	1988-10-13	1999-01-15	로쓰 비엠, 하우스 한스-루돌프	7-치환된-헵트-6-엔산 및 -헵탄산과 그의 유도체 및 그의 중간체의 제조방법
JPH04270285A (ja) *	1988-11-14	1992-09-25	Nissan Chem Ind Ltd	ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) *	1989-04-06	1990-10-11	Bayer Ag	Substituierte 1,8-naphthyridine
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) *	1989-08-22	1989-10-04	Fujisawa Pharmaceutical Co	Pyrroloquinoline compounds
IT1237792B (it) *	1989-12-21	1993-06-17	Zambon Spa	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE4243279A1 (de) *	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
JP2736599B2 (ja) *	1993-07-23	1998-04-02	株式会社キッツ	ボールバルブのシート構造
US6425881B1 (en)	1994-10-05	2002-07-30	Nitrosystems, Inc.	Therapeutic mixture useful in inhibiting lesion formation after vascular injury
ES2194202T3 (es) *	1996-06-24	2003-11-16	Novartis Ag	Compuestos polimorfos.
EP0988289A2 (en)	1997-06-05	2000-03-29	Takeda Pharmaceutical Company Limited	Heterocyclic compounds, their production and use
AU767154B2 (en)	1998-11-20	2003-10-30	Skyepharma Canada Inc.	Dispersible phospholipid stabilized microparticles
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
EP1284964A1 (en)	2000-05-26	2003-02-26	Ciba SC Holding AG	Process for the preparation of indole derivatives and intermediates of the process
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
CN1509180A (zh)	2001-04-18	2004-06-30	ԭ��ø�	用脂肪族聚胺治疗综合症x的方法
AU2002333271B2 (en) *	2001-08-03	2007-08-09	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of fluvastatin sodium
US6696473B2 (en)	2001-12-21	2004-02-24	X-Ceptor Therapeutics, Inc.	Heterocyclic modulators of nuclear receptors
EP1496897A4 (en)	2002-04-12	2006-05-10	Merck & Co Inc	INHIBITORS OF TYROSINE KINASES
CA2535359A1 (en)	2003-08-21	2005-03-03	Merck Frosst Canada Ltd.	Cathepsin cysteine protease inhibitors
EP1510208A1 (en)	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) *	2003-08-27	2008-07-23	住友化学株式会社	芳族不饱和化合物的制备方法
US8227434B1 (en)	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
US7709508B2 (en)	2004-12-09	2010-05-04	Merck Sharp & Dohme	Estrogen receptor modulators
CA2590860C (en)	2004-12-09	2011-05-03	Merck & Co., Inc.	Estrogen receptor modulators
PL1855674T3 (pl)	2005-03-02	2015-01-30	Merck Sharp & Dohme	Kompozycja do hamowania katepsyny K
KR101363278B1 (ko)	2005-06-27	2014-02-21	엑셀리시스 페이턴트 컴퍼니 엘엘씨	이미다졸계 ｌｘｒ 변조제
WO2007017117A1 (en) *	2005-07-28	2007-02-15	Lek Pharmaceuticals D.D.	Process for the synthesis of rosuvastatin calcium
US8440695B2 (en)	2005-11-09	2013-05-14	St Jude Children's Research Hospital	Use of chloroquine to treat metabolic syndrome
PL2010528T3 (pl)	2006-04-19	2018-03-30	Novartis Ag	6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
ATE431818T1 (de)	2006-04-20	2009-06-15	Italiana Sint Spa	Verfahren zur herstellung von fluvastatin-natrium
RS53461B (en)	2006-07-05	2014-12-31	Takeda Gmbh	COMBINATION OF HMG-COA REDUCTASE INHIBITOR OR SIMVASTATIN WITH PHOSPHODIESTERASE 4 INHIBITOR AS A ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA019951B1 (ru)	2007-03-01	2014-07-30	Новартис Аг	Ингибиторы киназы pim и способы их применения
KR20100017866A (ko)	2007-05-21	2010-02-16	노파르티스 아게	Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법
ES2330184B1 (es)	2008-06-03	2010-07-05	Neuron Biopharma, S.A.	Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
SI2373609T1 (sl)	2008-12-19	2013-12-31	Krka, D.D., Novo Mesto	Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CA2761934C (en)	2009-05-28	2018-01-09	Exelixis Patent Company Llc	Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2010144909A1 (en)	2009-06-12	2010-12-16	Novartis Ag	Fused heterocyclic compounds and their uses
EP2519517B1 (en)	2009-12-29	2015-03-25	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
EA201290919A1 (ru)	2010-03-16	2013-03-29	Дана-Фарбер Кэнсер Инститьют, Инк.	Индазольные соединения и их применение
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
JPWO2012046772A1 (ja)	2010-10-06	2014-02-24	国立大学法人東京大学	リンパ浮腫予防治療剤
WO2012112363A1 (en)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
TW201242953A (en)	2011-03-25	2012-11-01	Bristol Myers Squibb Co	Imidazole prodrug LXR modulators
JP6106685B2 (ja)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
KR20140108705A (ko)	2011-12-29	2014-09-12	트러스티즈 오브 터프츠 칼리지	재생 및 염증 반응을 제어하기 위한 생체물질의 기능화
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
JP6442475B2 (ja)	2013-03-15	2018-12-19	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｌｘｒ調節因子
EP2810644A1 (en)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Oral formulation for the treatment of cardiovascular diseases
AU2014332250B2 (en)	2013-10-08	2018-07-19	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015051479A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015120580A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10550121B2 (en)	2015-03-27	2020-02-04	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases

1983
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/de active IP Right Grant
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 CA CA000441684A patent/CA1210405A/en not_active Expired
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 EP EP83810548A patent/EP0114027B1/en not_active Expired
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284A/da not_active Application Discontinuation
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown

Also Published As

Publication number	Publication date
NL950022I2 (nl)	1996-12-02
EP0114027A1 (en)	1984-07-25
DE19475017I2 (de)	2003-02-20
AU2261283A (en)	1984-06-18
FI77228C (fi)	1989-02-10
DK359284D0 (da)	1984-07-20
FI77228B (fi)	1988-10-31
IE832713L (en)	1984-05-22
GR79042B (da)	1984-10-02
WO1984002131A1 (en)	1984-06-07
DK165244B (da)	1992-10-26
FI842615A0 (fi)	1984-06-28
DK165244C (da)	1993-03-22
CA1210405A (en)	1986-08-26
DK359284A (da)	1984-07-20
ATE31718T1 (de)	1988-01-15
IE56262B1 (en)	1991-06-05
DE3375137D1 (en)	1988-02-11
FI842615A (fi)	1984-06-28
DK97890A (da)	1990-04-19
EP0114027B1 (en)	1988-01-07
JPH0347167A (ja)	1991-02-28
CY1579A (en)	1991-12-20
LU88670I2 (fr)	1996-04-29
HU204253B (en)	1991-12-30
AU570021B2 (en)	1988-03-03
IL70286A (en)	1987-08-31
HK11191A (en)	1991-02-13
IL70286A0 (en)	1984-02-29
HUT35642A (en)	1985-07-29
JPH0440343B2 (da)	1992-07-02
NZ206338A (en)	1987-08-31
NL950022I1 (da)	1996-01-02

Legal Events

Date	Code	Title	Description
1996-02-26	CTFF	Application for supplementary protection certificate (spc) filed	Free format text: CA 1996 00001, 960118
1997-04-21	CTFG	Supplementary protection certificate (spc) issued	Free format text: CA 1996 00001, 960118, EXPIRES: 20080823
2003-12-08	PUP	Patent expired

Publication	Publication Date	Title
DK97890D0 (da)	1990-04-19	Fremgangsmaade til fremstilling af mevalolactonanaloge
NZ214402A (en)	1989-01-27	Indene derivatives and pharmaceutical compositions
ATE181482T1 (de)	1999-07-15	Herbizide zusammensetzungen in form einer diphenylether- und stickstofflösung und verfahren
PT80674A (en)	1985-07-01	Process for the preparation of pyrazole analogues of mevalonolactone and derivatives thereof
ES529090A0 (es)	1986-07-16	Procedimiento para preparar analogos de mevalonolactona y derivados de los mismos
EP0086756A3 (en)	1984-11-28	Dermatological compositions based on mercaptopropionylamidoacetic thiol esters